Aiolos Bio Inc launched as a new company on 24 October with an asset for the treatment of asthma and $245 million in Series A financing from a syndicate co-led by Forbion, Atlas Venture, Bain Capital Life Sciences, and Sofinnova Investments. The launch was announced just two months after Aiolos acquired rights to a monoclonal antibody that inhibits thymic stromal lymphopoietin (TSLP) from a company in China. TSLP is a cytokine and regulator of the immune response to allergens, viruses and pollutants.
